Cognition Therapeutics is focused on developing innovative therapies that improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. We deeply thank the patients, families, clinical researchers, hospitals and clinics that participate in clinical trials that are designed to test our lead drug candidate, CT1812.
Every patient who participates allows us to learn more about the safety and effectiveness of this experimental medicine and contributes to the overall understanding of Alzheimer’s disease. This benefits all current and future patients, and both directly and indirectly their families and caregivers.
We are currently conducting a clinical trial in Australia of our drug candidate CT1812 in Alzheimer’s disease patients. For information, please visit clinicaltrials.gov, an internet-based resource maintained by the National Library of Medicine of the National Institutes of Health, by clicking here.
At this time, Cognition Therapeutics is not conducting clinical trials for CT1812 in the United States.
Pre-approval Access to CT1812
Programs for access to an experimental medicine prior to regulatory approval, often called “compassionate use” or “expanded access” programs, exist so that physicians can request an experimental medication outside of a clinical trial setting in order to treat a patient with a serious or life-threatening condition not adequately treated with already approved medicines. To learn about Cognition’s Pre-approval Access policy, please click here.